双时间点[18F]FDG-PET/CT作为胸膜间皮瘤免疫治疗预后生物标志物
基于NIPU试验(NCT04300244)的探索性分析,胸膜间皮瘤患者分别在基线(n=50)和第5周(n=45)接受双时间点[18F]FDG-PET/CT,42例完成两次检查。第5周滞留指数(RI)三分位与总生存(OS,p=0.038)和无进展生存(PFS,p=0.031)呈阶梯式分离,最低三分位预后最佳;SUV60min三分位也与OS(p=0.042)和PFS(p=0.043)显著相关,但OS呈非单调模式。客观缓解者第5周RI和SUV60min显著更低;基线RI三分位与OS或PFS无关。
要点
- 第5周DTP-PET的RI三分位与OS和PFS呈阶梯式关联,最低三分位预后最佳。
- 第5周RI和SUV60min在客观缓解者中显著更低。
- 基线RI三分位与OS或PFS无关,结论需更大队列验证。
核心结论
- 第5周[18F]FDG DTP-PET在胸膜间皮瘤免疫治疗患者中提示预后价值,RI与生存呈一致阶梯式关联,SUV60min对OS呈非单调关系。
研究设计与样本
- 来自NIPU试验(NCT04300244)的患者在基线(n=50)和/或第5周(n=45)接受DTP-PET,42例完成两次检查。
- 在60和120分钟于最摄取病灶中心2-cm球形VOI测量峰值SUV,RI为两时间点间百分比变化。
- 基于RI和SUV60min三分位,用Kaplan-Meier曲线和Cox比例风险模型分析OS和PFS。
- 客观缓解和疾病控制分别按mRECIST和iRECIST定义,组间比较用Wilcoxon秩和检验。
主要发现
- 第5周RI三分位对OS(p=0.038)和PFS(p=0.031)呈阶梯式分离,最低三分位预后最佳。
- 第5周SUV60min三分位与OS(p=0.042)和PFS(p=0.043)显著相关,但OS呈中间三分位生存最差的非单调模式。
- 客观缓解者第5周RI和SUV60min显著更低。
- 基线RI三分位与OS或PFS无关联。
关键数值与推荐
- RI定义为60与120分钟峰值SUV之间的百分比变化。
- 峰值SUV在最大摄取病灶中心2-cm球形VOI内测量。
- 客观缓解和疾病控制分别采用mRECIST和iRECIST标准。
- 生存分析基于RI和SUV60min三分位分组。
临床怎么用
- 对于接受免疫治疗的胸膜间皮瘤患者,可考虑在第5周行双时间点[18F]FDG-PET/CT评估RI和SUV60min以辅助预后判断。
- 第5周RI和SUV60min较低可能提示客观缓解,但需结合mRECIST/iRECIST标准综合判断。
- 基线RI不宜单独用于预后分层。
局限性
- 作者声明 findings 为探索性,需更大队列验证。
- 需进一步研究探索潜在生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [18F]FDG PET/CT provides a non-invasive assessment of tumour glucose metabolism. While conventional PET/CT captures a single time point, dual-time-point PET/CT (DTP-PET) evaluates metabolic dynamics by acquiring images at two defined times after injection. This study investigated whether the change in [18F]FDG uptake between 60 and 120 min-retention index (RI)-predicts clinical outcomes in patients with pleural mesothelioma (PM) receiving immunotherapy. Patients from the NIPU trial (NCT04300244) underwent DTP-PET at baseline (n = 50) and/or week-5 (n = 45), with 42 completing both. Peak SUV was measured in a 2-cm spherical volume of interest centred on the most avid lesion at 60 and 120 min, and RI was calculated as the percentage change between the two. Survival (OS, PFS) was analysed using Kaplan-Meier curves and Cox proportional hazards models based on tertiles of RI and SUV60min. Objective response and disease control were defined by mRECIST and iRECIST. Group comparisons used the Wilcoxon rank-sum test. RESULTS: At week-5, RI tertiles showed stepwise separation for both OS (p = 0.038) and PFS (p = 0.031), with the lowest tertile associated with the most favourable outcomes. SUV60min tertiles were also significantly associated with OS (p = 0.042) and PFS (p = 0.043), though OS exhibited a non-monotonic pattern in which the middle tertile had the poorest survival. Objective responders displayed significantly lower RI and SUV60min at week-5. Baseline RI tertiles were not associated with OS or PFS. CONCLUSIONS: Week-5 [18F]FDG DTP-PET suggests prognostic value in PM patients receiving immunotherapy. Both RI and SUV60min were associated with objective response. RI showed a consistent stepwise association with survival, whereas SUV60min showed a non-monotonic relationship for OS. These findings are exploratory and require validation in larger cohorts. Further studies are warranted to explore underlying biological mechanisms. TRIAL REGISTRATION: ClinicalTrials.gov NCT04300244. Registered 2020-03-09. https://clinicaltrials.gov/study/NCT04300244.
引用
- Thunold S, Hernes E, Gyland Mikalsen LT, et al. Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy. EJNMMI Res. 2026. PMID: 42322509. doi:10.1186/s13550-026-01469-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。